Lipocine Inc. (LPCN): Price and Financial Metrics


Lipocine Inc. (LPCN): $0.44

-0.01 (-2.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

LPCN POWR Grades

  • Sentiment is the dimension where LPCN ranks best; there it ranks ahead of 90.68% of US stocks.
  • The strongest trend for LPCN is in Stability, which has been heading up over the past 37 days.
  • LPCN ranks lowest in Momentum; there it ranks in the 13th percentile.

LPCN Stock Summary

  • For LPCN, its debt to operating expenses ratio is greater than that reported by only 0.52% of US equities we're observing.
  • With a year-over-year growth in debt of -100%, LIPOCINE INC's debt growth rate surpasses just 0% of about US stocks.
  • As for revenue growth, note that LPCN's revenue has grown 30,059.37% over the past 12 months; that beats the revenue growth of 99.93% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to LIPOCINE INC are MRSN, EBET, ZOM, MDGS, and KROS.
  • Visit LPCN's SEC page to see the company's official filings. To visit the company's web site, go to www.lipocine.com.

LPCN Valuation Summary

  • In comparison to the median Healthcare stock, LPCN's price/earnings ratio is 58.55% lower, now standing at 9.7.
  • Over the past 111 months, LPCN's EV/EBIT ratio has gone up 2067.8.

Below are key valuation metrics over time for LPCN.

Stock Date P/S P/B P/E EV/EBIT
LPCN 2022-12-02 2.4 1.1 9.7 9.0
LPCN 2022-12-01 2.4 1.1 9.9 9.1
LPCN 2022-11-30 2.4 1.1 9.7 9.0
LPCN 2022-11-29 2.3 1.0 9.5 8.8
LPCN 2022-11-28 2.4 1.1 9.9 9.1
LPCN 2022-11-25 2.5 1.1 10.3 9.6

LPCN Growth Metrics

    Its year over year net cashflow from operations growth rate is now at 73.51%.
  • Its 5 year net cashflow from operations growth rate is now at 34.14%.
  • Its 3 year price growth rate is now at -57.19%.
Over the past 52 months, LPCN's revenue has gone up $16,157,813.

The table below shows LPCN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 16.58584 -1.135365 4.095298
2022-06-30 16.64084 -4.917978 3.423166
2022-03-31 16.14084 -4.234931 -0.754098
2021-12-31 16.14084 -4.411303 -0.634399
2021-09-30 0.054994 -17.08987 -17.7697
2021-06-30 0 -14.27264 -19.00166

LPCN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LPCN has a Quality Grade of D, ranking ahead of 21.42% of graded US stocks.
  • LPCN's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
  • ZTS, MDWD, and GERN are the stocks whose asset turnover ratios are most correlated with LPCN.

The table below shows LPCN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 NA -1.022
2021-03-31 0.000 NA -1.500
2020-12-31 0.000 NA -4.723
2020-09-30 0.000 NA -3.288
2020-06-30 0.008 1 -2.946
2020-03-31 0.008 1 -1.844

LPCN Price Target

For more insight on analysts targets of LPCN, see our LPCN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.75 Average Broker Recommendation 1.33 (Strong Buy)

LPCN Stock Price Chart Interactive Chart >

Price chart for LPCN

LPCN Price/Volume Stats

Current price $0.44 52-week high $1.89
Prev. close $0.45 52-week low $0.36
Day low $0.44 Volume 11,255
Day high $0.46 Avg. volume 426,609
50-day MA $0.43 Dividend yield N/A
200-day MA $0.81 Market Cap 38.95M

Lipocine Inc. (LPCN) Company Bio


Lipocine develops pharmaceutical products using its oral drug delivery technology in the areas of men’s and women’s health, with a current focus being testosterone replacement. The company was founded in 1997 and is based in Salt Lake City, Utah.


LPCN Latest News Stream


Event/Time News Detail
Loading, please wait...

LPCN Latest Social Stream


Loading social stream, please wait...

View Full LPCN Social Stream

Latest LPCN News From Around the Web

Below are the latest news stories about LIPOCINE INC that investors may wish to consider to help them evaluate LPCN as an investment opportunity.

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the third quarter and nine months ended September 30, 2022 and provided a corporate update.

Yahoo | November 9, 2022

Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating CNS disorders by leveraging its proprietary platform to develop differentiated products, today announced George Nomikos, M.D., Ph.D., has joined Lipocine as Chief Medical Officer and Spyros Papapetropoulos, M.D. Ph.D., has been appointed Lead Director and Chairman of the Board.

Yahoo | November 3, 2022

Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products through the oral delivery of previously difficult to deliver molecules focused on treating CNS disorders, announced today that it will present at the H.C. Wainwright 6th Annual NASH Investor Conference to be held virtually on October 17.

Yahoo | October 11, 2022

Lipocine to Participate in the Cantor Neurology & Psychiatric Conference

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products through the oral delivery of previously difficult to deliver molecules focused on treating CNS disorders, announced today that it will participate in the Cantor Neurology & Psychiatric Conference (October 6-7) in San Francisco.

Yahoo | September 27, 2022

Lipocine To Focus On Central Nervous System Conditions; Explores Partnerships For Non-Core Assets

Lipocine Inc (NASDAQ: LPCN) announced its plans to focus on treating Central Nervous System (CNS) disorders. The company's priority is to advance its endogenous neuroactive steroids (NAS) pipeline. The CNS development portfolio includes LPCN 1154, a fast-acting oral antidepressant for postpartum depression (PPD) with potential for outpatient use; LPCN 2101 for women with epilepsy; and additional undisclosed CNS-focused candidates. Lipocine's most advanced NAS candidate is LPCN 1154, a non-invasi

Yahoo | September 26, 2022

Read More 'LPCN' Stories Here

LPCN Price Returns

1-mo 11.17%
3-mo -19.22%
6-mo -52.17%
1-year -56.44%
3-year 12.82%
5-year -87.50%
YTD -55.60%
2021 -27.13%
2020 253.34%
2019 -70.39%
2018 -62.21%
2017 -6.52%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7942 seconds.